Dorris John R, Jones Suzanne
Sarah Cannon Research Institute, Nashville, TN, USA.
Sarah Cannon Research Institute, Nashville, TN, USA
Ann Pharmacother. 2014 Sep;48(9):1194-1201. doi: 10.1177/1060028014542415. Epub 2014 Jul 9.
To highlight the potential role of pharmacists in facilitating use of everolimus in breast cancer and increase practitioner knowledge of everolimus therapy to enhance patient outcomes.
A PubMed (1966 to May 2013) search included the terms everolimus, breast cancer, adverse events (AEs), pharmacist, and pharmacy. Abstracts presented at the American Society of Clinical Oncology 2012 Annual Meeting were also reviewed.
Articles published in English and directly related to everolimus clinical trials in breast cancer and other cancers were included, as were general pharmacy practice articles.
Phase 3 clinical trials are currently exploring the efficacy of everolimus in combination therapy for breast cancer and the pharmacotherapeutical implications of the drug's mechanism of action in relation to the PI3K/Akt pathway. Everolimus treatment-related topics relevant for pharmacists include drug administration, AE profile, potential drug interactions, dose adjustments, and comorbidity management. This comprehensive literature review of all components of everolimus treatment reveals the complexity of this treatment approach and the need for increased pharmacist involvement.
Research based on the current treatment landscape and health care delivery system shows that pharmacists can greatly enhance patient care by providing teaching as part of a comprehensive cancer treatment approach. Because of their advanced knowledge of pharmacotherapy, pharmacists can directly support safe and effective use of everolimus while promoting optimal patient outcomes through a multidisciplinary approach that addresses comorbid conditions; they can also provide effective counseling and patient teaching in an ever-changing health care delivery system.
强调药剂师在促进依维莫司用于乳腺癌治疗方面的潜在作用，并增加从业者对依维莫司治疗的了解，以改善患者治疗效果。
对PubMed（1966年至2013年5月）进行检索，检索词包括依维莫司、乳腺癌、不良事件（AE）、药剂师和药学。还对2012年美国临床肿瘤学会年会发表的摘要进行了回顾。
纳入以英文发表的、与依维莫司在乳腺癌及其他癌症中的临床试验直接相关的文章，以及一般药学实践文章。
3期临床试验目前正在探索依维莫司联合治疗乳腺癌的疗效，以及该药物作用机制在PI3K/Akt通路方面的药物治疗意义。与药剂师相关的依维莫司治疗主题包括给药、AE概况、潜在药物相互作用、剂量调整和合并症管理。对依维莫司治疗所有组成部分的这一全面文献综述揭示了这种治疗方法的复杂性以及药剂师更多参与的必要性。
基于当前治疗格局和医疗保健提供系统的研究表明，药剂师作为综合癌症治疗方法的一部分提供教学，可极大地改善患者护理。由于药剂师在药物治疗方面的专业知识，他们可以直接支持依维莫司的安全有效使用，同时通过解决合并症的多学科方法促进实现最佳患者治疗效果；他们还可以在不断变化的医疗保健提供系统中提供有效的咨询和患者教育。
